BioSpace News Archive

Vitrolife AB (publ) Interim report Q2, 2022: Together for successful growth.

HMPL-A83 is the thirteenth innovative oncology drug candidate discovered in-house by HUTCHMED and its second large molecule drug candidate to enter clinical studies

SpringWorks Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on developing life-changing medicines for patients with severe rare diseases and cancer, announced the appointment of Carlos Albán to the Company’s Board of Directors.

Nutriband Inc. announced that it has received a verdict in favor of the company, where the company prevailed on all issues, relating to the lawsuit the company filed to rescind the acquisition of Advanced Health Brands in 2017.

Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, announced that the Company granted non-statutory stock options to new employees as inducement awards outside of the Company’s 2019 Stock Incentive Plan.

First Wave BioPharma, Inc. (NASDAQ:FWBI) (“First Wave BioPharma” or the “Company”), a clinical-stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal diseases, today announced that it has entered into a securities purchase agreement with several institutional accredited investors for the issuance and sale of (i) an aggregate of 150 shares of its Series D Convertible Preferred Stock.

Roquefort Therapeutics, the Main Market listed biotech company focused on early-stage opportunities in the biotechnology sector, is pleased to announce that trading in the Company’s Ordinary Shares of one pence each has commenced on the OTCQB Venture Market in the United States.

NovaBay® Pharmaceuticals, Inc., a pharmaceutical company developing and commercializing high-quality, scientifically formulated eyecare and skincare products, announces record sales of Avenova-branded products during Amazon’s Prime Day event.

Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced that the company will host a conference call and live webcast on Thursday, August 4, 2022 at 5:00 p.m. ET to report second quarter 2022 financial results and discuss recent business highlights.

Waypoint Orthopedics, Inc., a spinal instrumentation company, announced the company’s recent submission of an FDA 510(k) application for the Waypoint GPS™ - a smart bone awl for use during pedicle screw pilot hole drilling.